Mira Pharmaceuticals Inc MIRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
-
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
-
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND
-
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
-
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies
Trading Information
- Previous Close Price
- $0.63
- Day Range
- $0.60–0.66
- 52-Week Range
- $0.60–1.80
- Bid/Ask
- $0.62 / $0.62
- Shares Outstanding
- 42.02M
- Market Cap
- $26.03M
- Volume/Avg
- 106,231 / 573,821
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Growth
- Total Number of Employees
- 2
Valuation
|
Metric
|
MIRA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.19 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MIRA
|
|---|---|
Quick Ratio | 198.75 |
Current Ratio | 200.08 |
Interest Coverage | — |
Quick Ratio
MIRA
Profitability
|
Metric
|
MIRA
|
|---|---|
Return on Assets (Normalized) | −59.06% |
Return on Equity (Normalized) | −61.09% |
Return on Invested Capital (Normalized) | −63.16% |
Return on Assets
MIRA
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|!<&^Ztb | LOCK|bMZ | $1T | |||
| Johnson & Johnson
JNJ
| LOCK|F#B#?&# | LOCK|Y$# | $635B | |||
| AbbVie Inc
ABBV
| LOCK|%dp>YZ | LOCK|FD% | $505B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|!?%f^K?& | LOCK|>D! | $381B | |||
| Merck & Co Inc
MRK
| LOCK|yH$YCx | LOCK|TQ> | $358B | |||
| Novartis AG ADR
NVS
| LOCK|^>!@%%^T | LOCK|V#@ | $297B | |||
| AstraZeneca PLC
AZN
| LOCK|r@TC<vhY | LOCK|@? | $267B | |||
| Amgen Inc
AMGN
| LOCK|&v$K@h@> | LOCK|@>L | $237B | |||
| Gilead Sciences Inc
GILD
| LOCK|@<wx%#c | LOCK|rw< | $193B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|!g#>r$l | LOCK|&@x | $172B |
United States